We work with the Innovative Medicines Initiative 2 (IMI2), the world’s biggest public-private partnership for health, as co-leaders of the latest pain initiative.
The Pain Group of the IMI2 unites European pharmaceutical companies dedicated to better understand, treat and manage pain. The framework of the public-private partnership enables a portfolio of pain projects addressing a broad spectrum of relevant challenges together with the best skilled public consortia of expert academics, hospitals, small and medium-sized enterprises (SMEs) and patient groups.
The IMI is a public-private partnership between the EU and EFPIA (European Federation of Pharmaceutical Industries and Associations) companies and is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas of unmet medical and social need.
Paving the way for safe, effective treatments
The first collaborative project with the IMI2 started in April 2017, with the aim of increasing our knowledge of pain targets and pathways to generate predictive research approaches for the discovery of disease-modifying analgesics. The Modelling Neuron-Glia Networks into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) project will, over the course of 3 years, investigate neuron-glia interactions by developing authentic cellular (co-culture) assays using neuronal and glial cell types derived from human induced pluripotent stem cells (iPSC).
Patient engagement in research and health system decision-making processes
PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines
The public-private partnership PARADIGM started in March 2018 and aims to establish best practice for effective and meaningful engagement of patients in the life cycle of medicines for better health outcomes.
Improving the care of acute and chronic pain patients
We are currently planning a second pain project that seeks to improve the care of patients suffering from acute or chronic pain, which will start in 2018. We look forward to the ground-breaking results from these and other IMI2-supported pain projects in the years to come.
Creating a network of partnerships
In addition, Grünenthal will join other IMI2 projects to establish networks of specialists starting in 2018 or 2019: the ‘European Screening Center Unique Library of Attractive Biology’ (ESCulab), and ‘Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice’.
The Neurobiology of the Placebo Effect – The 1st PainSolve Webinar
We are delighted to have had Prof. Ulrike Bingel (University Hospital Essen, Germany) host our inaugural PainSolve webinar on the 12th December 2018, titled, ‘Psychological and Neurobiological Mechanisms of Placebo and Nocebo Responses.’Discover more
How can the patient experience inform your research?
Chronic pain affects every aspect of patients’ lives. However, the experience of pain is unique to the individual, which is why effective treatment is challenging. This article summarises a patient-centric approach to research that harnesses patient insights to inform the development of new strategies with the potential for greater impact on the lives of those with chronic pain.Discover more
Diagnostic Challenges of Small Fibre Neuropathy
In this article Prof. Páll Karlsson (Aarhus University) highlights the need for a gold standard in the diagnosis of small fibre neuropathy (SFN). Prof. Karlsson focuses on the heterogeneity of SFN as a potential cause of this unmet need, by comparing different characteristics of the disease and those of similar diseases.Discover more
Convergences in PP
Convergences in Pelvi-Perineal Pain is a society that aims to promote knowledge about chronic perineal pain. Over the 2-day programme of this society’s 2018 Congress in Brussels, there were many insightful talks by some of the top researchers and clinicians in this field, an overview of these are discussed in this article.Discover more